A
Aristotelis Bamias
Researcher at National and Kapodistrian University of Athens
Publications - 238
Citations - 9828
Aristotelis Bamias is an academic researcher from National and Kapodistrian University of Athens. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 36, co-authored 208 publications receiving 7174 citations. Previous affiliations of Aristotelis Bamias include Alexandra Hospital & Hebron University.
Papers
More filters
Journal ArticleDOI
Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial
Eric Pujade-Lauraine,Felix Hilpert,Béatrice Weber,Alexander Reuss,Andreas Poveda,Gunnar B. Kristensen,Roberto Sorio,Ignace Vergote,Petronella O. Witteveen,Aristotelis Bamias,Deolinda Pereira,Pauline Wimberger,Ana Oaknin,Mansoor Raza Mirza,Philippe Follana,David T. Bollag,Isabelle Ray-Coquard +16 more
TL;DR: Adding bevacizumab to chemotherapy statistically significantly improved PFS and ORR; the OS trend was not significant.
Journal ArticleDOI
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.
Thomas Powles,Ignacio Duran,Michiel S. van der Heijden,Yohann Loriot,Nicholas J. Vogelzang,Ugo De Giorgi,Stéphane Oudard,Margitta Retz,Daniel Castellano,Aristotelis Bamias,Aude Flechon,Gwenaelle Gravis,Syed A. Hussain,Toshimi Takano,Ning Leng,Edward E. Kadel,Romain Banchereau,Priti S. Hegde,Sanjeev Mariathasan,Na Cui,Xiaodong Shen,Christina Louise Derleth,Marjorie C. Green,Alain Ravaud +23 more
TL;DR: Atezolizumab was not associated with significantly longer overall survival than chemotherapy in patients with platinum-refractory metastatic urothelial carcinoma overexpressing PD-L1, thus precluding further formal statistical analysis.
Journal ArticleDOI
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial.
Matthew D. Galsky,Jose Angel Arranz Arija,Aristotelis Bamias,Ian D. Davis,Maria De Santis,Eiji Kikuchi,Xavier Garcia-del-Muro,Ugo De Giorgi,Marina Mencinger,Kouji Izumi,Stefano Panni,Mahmut Gumus,Mustafa Ozguroglu,Arash Rezazadeh Kalebasty,Se Hoon Park,Boris Alekseev,Fabio A.B. Schutz,Jian Ri Li,Dingwei Ye,Nicholas J. Vogelzang,Sandrine Bernhard,Darren Tayama,Sanjeev Mariathasan,Almut Mecke,Ann Christine Thastrom,Enrique Grande +25 more
TL;DR: The results of IMvigor130 support the use of atezolizumab plus platinum-based chemotherapy as a potential first-line treatment option for metastatic urothelial carcinoma and the safety profile of the combination was consistent with that observed with the individual agents.
Journal ArticleDOI
Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid
Meletios A. Dimopoulos,Efstathios Kastritis,Christina Bamia,Ioannis Melakopoulos,Dimitra Gika,Maria Roussou,Magdalini Migkou,Evangelos Eleftherakis-Papaiakovou,Dimitrios Christoulas,Evangelos Terpos,Aristotelis Bamias +10 more
TL;DR: The risk of developing Osteonecrosis of the jaw after treatment of zoledronic acid is reduced (but not deleted) by the implementation of preventive measures.
Journal ArticleDOI
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
Ronald de Wit,Johann S. de Bono,Cora N. Sternberg,Karim Fizazi,Bertrand Tombal,Christian Wülfing,Gero Kramer,Jean-Christophe Eymard,Aristotelis Bamias,Joan Carles,Roberto Iacovelli,Bohuslav Melichar,Ásgerður Sverrisdóttir,Christine Theodore,Susan Feyerabend,Carole Helissey,Ayse Ozatilgan,Christine Geffriaud-Ricouard,Daniel Castellano,Card Investigators +19 more
TL;DR: Cabazitaxel significantly improved a number of clinical outcomes, as compared with the androgen-signaling-targeted inhibitor (abiraterone or enzalutamide), in patients with metastatic castration-resistant prostate cancer who had been previously treated with docetaxel and the alternative androgen